GDC-0941 is an oral class I pan-PI3K inhibitor with activity in the nanomolar range against a wide range of cancer cell lines that has preclinical activity in models harbouring pathway alterations in PIK3CA, PTEN, or HER2 [24]. Here, PIK3CB is linked to cancer.